Applicant: Mei-Chiao Wu et al. Attorney's Docket No.: 11702-003006 / PE-21602-

Serial No.: 10/697,741 Filed: October 30, 2003

Page : 2 of 5

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-32. (Cancelled)

- 33. (Previously Presented) A pharmaceutical composition comprising a product obtained from a process for obtaining a pharmacologically active composition from a culture of *Antrodia camphorata*, the process comprising:
- (a) preparing a first culture by inoculating a mycelial inoculum of an isolate of *Antrodia camphorata* into a liquid medium suitable for growth of said isolate;
 - (b) cultivating the first culture resulting from step (a);
- (c) harvesting a pharmacologically active solution by removing a major portion of insoluble substances from the culture of step (b); and
- (d) subjecting the solution from step (c) to selective separation based on molecular weight, such that a pharmacologically active composition containing fungal molecules having molecular weights of no more than about 10kDa is obtained.

34-40. (Cancelled)

- 41. (Previously Presented) The pharmaceutical composition of claim 33, wherein the isolate of *Antrodia camphorata* is selected from CCRC 930032, CCRC 35396, CCRC 35398, CCRC 35716, CCRC 36401, and CCRC 36795.
- 42. (Previously Presented) The pharamaceutical composition of claim 33, wherein step (b) includes the following sub-steps:
- (i) subjecting the first culture obtained in step (a) to a first stage of agitation which is set at a first predetermined rate and for a first period of time to allow growth of the inoculated isolate, such that a second culture with proliferated mycelia is obtained; and

Applicant: Mei-Chiao Wu et al. Attorney's Docket No.: 11702-003006 / PE-21602-

Serial No.: 10/697,741 : October 30, 2003 Filed

Page : 3 of 5

(ii) subjecting the second culture obtained from step (i) to a second stage of agitation which is set at a second predetermined rate higher than the first predetermined rate, so that the isolate grown in the second culture is cultivated under physiological stress.

- (Previously Presented) The pharmaceutical composition of claim 42, wherein sub-43. steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.5 to 5.4.
- 44. (Previously Presented) The pharmaceutical composition of claim 42, wherein substeps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.6 to 5.3.
- (Previously Presented) The pharmaceutical composition of claim 42, wherein sub-45. steps (i) and (ii), the first and second subculture are cultivated at a pH value between 4.7 to 5.2.
- (Previously Presented) The pharmaceutical composition of claim 33, wherein the 46. liquid medium used in step (a) is potato dextrose broth.
- (Previously Presented) The pharmaceutical composition of claim 33, wherein the 47. liquid medium used in step (a) is a synthetic medium containing fructose as a major carbon source.

48-59. (Cancelled)